NMRD Key Statistics, Chart & Performance
The current stock price of NMRD is 0.1053 USD. In the past month the price decreased by -54.22%. In the past year, price decreased by -94.2%.
NMRD Technical Analysis
NMRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRD. NMRD has a bad profitability rating. Also its financial health evaluation is rather negative.
NMRD Financial Highlights
Over the last trailing twelve months NMRD reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 39.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMRD Forecast & Estimates
7 analysts have analysed NMRD and the average price target is 8.67 USD. This implies a price increase of 8133.62% is expected in the next year compared to the current price of 0.1053.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 43.63% for NMRD
NMRD Ownership
NMRD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.14 | 189.676B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.28 | 168.855B | ||
| SYK | STRYKER CORP | 23.93 | 138.597B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.42 | 115.097B | ||
| BDX | BECTON DICKINSON AND CO | 13.74 | 58.942B | ||
| IDXX | IDEXX LABORATORIES INC | 43.73 | 51.391B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.39 | 45.321B | ||
| RMD | RESMED INC | 21.91 | 38.981B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.54 | 37.494B | ||
| DXCM | DEXCOM INC | 27.61 | 27.258B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NMRD
Company Profile
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Company Info
NEMAURA MEDICAL INC
57 W 57th St
New York City NEW YORK 10019 US
CEO: Dewan Fazlul Hoque Chowdhury
Employees: 36
NEMAURA MEDICAL INC / NMRD FAQ
Can you describe the business of NEMAURA MEDICAL INC?
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Can you provide the latest stock price for NEMAURA MEDICAL INC?
The current stock price of NMRD is 0.1053 USD. The price decreased by -17.8% in the last trading session.
What is the dividend status of NEMAURA MEDICAL INC?
NMRD does not pay a dividend.
What is the ChartMill rating of NEMAURA MEDICAL INC stock?
NMRD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is NEMAURA MEDICAL INC (NMRD) stock traded?
NMRD stock is listed on the Nasdaq exchange.
What is NEMAURA MEDICAL INC worth?
NEMAURA MEDICAL INC (NMRD) has a market capitalization of 3.04M USD. This makes NMRD a Nano Cap stock.
Can you provide the ownership details for NMRD stock?
You can find the ownership structure of NEMAURA MEDICAL INC (NMRD) on the Ownership tab.